Starting in July of this year, the U.S. Food & Drug Administration (FDA) began issuing a series of recalls for heart medication valsartan—most due to entire batches of the drug testing positive for N-Nitrosodiethylamine (NDEA), a chemical that can lead to liver damage, tumors and,…
You might be familiar with Pradaxa—a blood-thinning medication that is used to prevent blood clots and strokes in heart arrhythmia patients and manufactured by Boehringer Ingelheim Pharmaceuticals Incorporated (BIPI). What you might not be aware of are the claims that their product marketing was misleading…
Stryker and National Plaintiff’s Leadership in MDL 2768 of the consolidated proceedings before Judge Talwani announced in Court this morning a proposed Master Settlement Agreement (MSA) for eligible claimants. The Stryker Hip Settlement includes those cases filed in the MDL 2768 in Massachusetts, the MCL…
In July, the Food and Drug Administration (FDA) issued a voluntary recall of multiple medications containing valsartan that were manufactured by the Chinese pharmaceutical company, Zhejiang Huahai. The recall occurred after two likely carcinogenic chemicals, N-nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA), were detected in the product—a…